InvestorsHub Logo
Followers 4
Posts 227
Boards Moderated 0
Alias Born 05/03/2018

Re: None

Friday, 07/06/2018 12:34:13 PM

Friday, July 06, 2018 12:34:13 PM

Post# of 425628
I love the scientific literature. On balance, that's the only reason I am here. Not only JELIS but sub-groups of AIM-HIGH and ACCORD. As well as the post PCI (Nosaka) and also CANTOS etc regarding inflammation. But funnily enough I never see any reference to the HPS2-THRIVE study where the subgroup analysis was NOT supportive!

Only issue I have is that Outcomes trial data is still one big unknown unknown, there is no way to know until we see the data.. and also how this fits within the context of PCSK9's. Even then.... why have there continued to be questions around the mineral oil placebo influencing statins, a subject the FDA surely must have addressed in the SPA that allowed them to continue with trial?





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News